

13 October 2023
ASX Announcement

ADALTA INVESTOR INFORMATION SESSIONS WITH IPF SURVIVOR BILL VAN NIEROP

MELBOURNE Australia, 13 October 2023: AdAlta Limited (ASX:1AD), the clinical stage drug discovery company developing novel therapeutic products from its i-body platform, is pleased to invite shareholders and potential investors to a series of upcoming events and presentations.

Following the recent commencement of the Phase I extension study for AD-214, AdAlta's CEO and Managing Director, Dr Tim Oldham will present investor updates at the Australian Shareholders Association Virtual Investment Summit 2023 and in person in Brisbane, Gold Coast, Sydney, Melbourne and Perth. The updates will cover recent scientific advances for AD-214 and update on business development activities and pipeline expansion opportunities.

AdAlta is delighted that Bill Van Nierop, a survivor of the typically fatal lung disease, Idiopathic Pulmonary Fibrosis (IPF), will join our Brisbane and Gold Coast events to discuss his experience with the disease and his recent Long Kayak for Lungs II down the Murrumbidgee River. This will highlight why it is important and valuable for AdAlta to be developing AD-214, its lead asset, for fibrotic disease. AdAlta plans to have recorded versions of Bill's remarks available at our other events.

Registration details for these upcoming events can be found below. The AdAlta investor relations team looks forward to welcoming all those shareholders and potential investors who are able to attend.

Authorised for lodgement by:
Tim Oldham
CEO and Managing Director
October 2023

BRIEFING OPTIONS FOR INVESTORS

<p>Australian Shareholders Association Virtual Investor Summit 2023</p> <p>CEO & Managing Director, Dr Tim Oldham will present virtually during the Small Cap Hour on Day 2.</p> <p>The virtual session will allow shareholders and potential investors the opportunity to hear an update on AD-214's clinical studies and out-licensing opportunities, along with multiple partnering opportunities within the i-body platform.</p> <p>Friday, 27 October 2023, 10:50am AEST Australian Shareholders Association Virtual Investor Summit 2023 (Day 2). Register link: Virtual Investor Summit</p>

<p>In-person briefings</p> <p>In-person briefing sessions will include presentations, an opportunity for Q&A and lunch. Places are limited for in-person events, so please register early. Register by COB Thursday 26 October 2023 by clicking the event location's link below and entering your name, email, contact details:</p>	
Brisbane:	<p>Monday, 30 October 2023, 12:15pm for 12:30pm start Piper Alderman, Level 26, Riparian Plaza, 71 Eagle Street, Brisbane Light lunch provided Register: Investor Briefing - Brisbane</p>
Gold Coast:	<p>Tuesday, 31 October 2023, 12:15pm for 12:30pm start Ladybird, 94 Seaworld Drive, Main Beach Lunch provided Register: Investor Briefing - Gold Coast</p>
Sydney:	<p>Wednesday, 1 November 2023, 12:15pm for 12:30pm start Piper Alderman, Level 23, Governor Macquarie Tower, 1 Farrer Place, Sydney Light lunch provided Register: Investor Briefing - Sydney</p>
Melbourne:	<p>Thursday, 2 November 2023, 12:15pm for 12:30pm start Piper Alderman, Level 23, 459 Collins Street, Melbourne Light lunch provided Register: Investor Briefing - Melbourne</p>
Perth:	<p>Friday, 3 November 2023, 12:15pm for 12:30pm start Piper Alderman, Level 29, 77 St Georges Terrace, Perth Light lunch provided Register: Investor Briefing - Perth</p>

Shareholders: please update your communication preferences



We encourage shareholders to update their share registry preferences to receive all communications electronically. Doing so helps us communicate with you in a time-efficient manner on important matters, while minimising our mail costs and environmental impact.

Simply [click here](#) or scan the QR code and follow the instructions.

Not a shareholder, but want to keep across our progress? [Click here](#) to subscribe to our updates using the Stay in Touch form.

Notes to Editors

About AdAlta

AdAlta Limited is a clinical stage drug development company headquartered in Melbourne, Australia. The Company is using its proprietary i-body technology platform to solve challenging drug targeting problems and generate a promising new class of single domain antibody protein therapeutics with the potential to treat some of today's most challenging medical conditions.

The i-body technology mimics the shape and stability of a unique and versatile antigen binding domain that was discovered initially in sharks and then developed as a human protein. The result is a range of unique proteins capable of interacting with high selectivity, specificity and affinity with previously difficult to access targets such as G-protein coupled receptors (GPCRs) that are implicated in many serious diseases. i-bodies are the first fully human single domain antibody scaffold and the first based on the shark motif to reach clinical trials.

AdAlta is extending Phase I clinical studies for its lead i-body candidate, AD-214, that is being developed for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other human fibrotic diseases for which current therapies are sub-optimal and there is a high unmet medical need. Preparation for Phase II clinical studies is also underway. AdAlta has a second target in discovery research, also in the field of fibrosis and inflammation.

The Company is also entering collaborative partnerships to advance the development of its i-body platform. It has a collaboration with Carina Biotech to co-develop precision engineered, i-body enabled CAR-T cell therapies (i-CAR-T) to bring new hope to patients with cancer. It has an agreement with GE Healthcare to co-develop i-bodies as diagnostic imaging agents (iPET imaging) against Granzyme B, a biomarker of response to immuno-oncology drugs, a program now in preclinical development.

AdAlta's strategy is to maximise the products developed using its next generation i-body platform by internally discovering and developing selected i-body enabled product candidates against GPCRs implicated in fibrosis, inflammation and cancer and partnering with other biopharmaceutical companies to develop product candidates against other classes of receptor, in other indications, and in other product formats.

Further information can be found at: <https://adalta.com.au>

For more information, please contact:

Investors

Tim Oldham, CEO & Managing Director
Tel: +61 403 446 665
E: t.oldham@adalta.com.au

Media

IR Department
Tel: +61 411 117 774
E: jane.lowe@irdepartment.com.au